Chromatin accessibility changes at intergenic regions are associated with ovarian cancer drug resistance.

ABSTRACT:

Background

Resistance to DNA damaging chemotherapies leads to cancer treatment failure and poor patient prognosis. We investigated how genomic distribution of accessible chromatin sites is altered during acquisition of cisplatin resistance using matched ovarian cell lines from high grade serous ovarian cancer (HGSOC) patients before and after becoming clinically resistant to platinum-based chemotherapy.

Results

Resistant lines show altered chromatin accessibility at intergenic regions, but less so at gene promoters. Clusters of cis-regulatory elements at these intergenic regions show chromatin changes that are associated with altered expression of linked genes, with enrichment for genes involved in the Fanconi anemia/BRCA DNA damage response pathway. Further, genome-wide dis

SUBMITTER: Gallon J 

PROVIDER: S-EPMC8180030 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature